DAVID SELIGSON, MD
Medical Practice at Le Conte Ave, Los Angeles, CA
License number
California G81853
Category
Medical Practice
Type
Clinical Pathology
License number
California G81853
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
Address
Address
10833 Le Conte Ave, Los Angeles, CA 90095
Phone
(310) 825-6877
Personal information
See more information about DAVID SELIGSON at radaris.comName
Address
Phone
4424 Stewart Ave, Los Angeles, CA 90066
819 N Citrus Ave #24, Azusa, CA 91702
3211 Nielsen Ct, Santa Rosa, CA 95404
827 35Th Ave, Santa Cruz, CA 95062
827 35Th Ave, Santa Cruz, CA 95062
Professional information
David Barish Seligson, Los Angeles CA
Specialties:
Medical Genetics, Pathology, Anatomic Pathology & Clinical Pathology, Anatomic Pathology, Clinical Pathology
Work:
UCLA Medical Center
10833 Le Conte Ave, Los Angeles, CA 90095
10833 Le Conte Ave, Los Angeles, CA 90095
Education:
Medical College of Wisconsin (1993)
Aromatase Expression Predicts Survival In Women With Non-Small Cell Lung Cancer
US Patent:
2010033, Dec 30, 2010
Filed:
Oct 6, 2008
Appl. No.:
12/681579
Inventors:
Lee Goodglick - Los Angeles CA, US
Richard J. Pietras - Sherman Oaks CA, US
Vei Mah - Davis CA, US
David B. Seligson - Los Angeles CA, US
David S. Chia - Santa Monica CA, US
Michael C. Fishbein - Encino CA, US
Richard J. Pietras - Sherman Oaks CA, US
Vei Mah - Davis CA, US
David B. Seligson - Los Angeles CA, US
David S. Chia - Santa Monica CA, US
Michael C. Fishbein - Encino CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
C40B 30/04, C12Q 1/26, G01N 33/573, C12Q 1/68
US Classification:
506 9, 435 25, 435 74, 435 6
Abstract:
The present invention relates to the discovery that the level of aromatase polypeptide expression in non-small cell lung carcinomas can be used for example to provide information useful in prognostic and therapeutic methodologies in women having or suspected of having this cancer.
Dr. David Seligson, Los Angeles CA - MD (Doctor of Medicine)
Specialties:
Medical Genetics
Address:
10833 Le Conte Ave SUITE 951732, Los Angeles 90095
(310) 825-6877 (Phone)
UCLA MEDICAL CENTER
10833 Le Conte Ave, Los Angeles 90095
(310) 794-9729 (Phone), (310) 794-6613 (Fax)
(310) 825-6877 (Phone)
UCLA MEDICAL CENTER
10833 Le Conte Ave, Los Angeles 90095
(310) 794-9729 (Phone), (310) 794-6613 (Fax)
Languages:
English
Education:
Medical School
Medical College of Wisconsin
Graduated: 1993
Medical College of Wisconsin
Graduated: 1993
Histone Modification Patterns For Clinical Diagnosis And Prognosis Of Cancer
US Patent:
2012009, Apr 19, 2012
Filed:
Apr 14, 2010
Appl. No.:
13/262219
Inventors:
David W. Dawson - Pacific Palisades CA, US
Siavash K. Kurdistani - Los Angeles CA, US
David B. Seligson - Los Angeles CA, US
Siavash K. Kurdistani - Los Angeles CA, US
David B. Seligson - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/7068, C40B 30/04, A61P 35/00, G01N 33/566
US Classification:
514 49, 435 71, 506 9
Abstract:
The present invention provides methods of diagnosing and providing a prognosis and therapy for cancer including, but not limited to, pancreatic cancer and responsiveness to thymidylate synthase inhibitor (e.g., 5-FU) therapy, by identifying cancers with altered histone modification patterns selected from the group consisting of H3K4me2, H3K9me2, or H3K18ac.
Antibodies Against Histone Modifications For Clinical Diagnosis And Prognosis Of Cancer
US Patent:
2008024, Oct 9, 2008
Filed:
May 1, 2006
Appl. No.:
11/912429
Inventors:
Siavash K. Kurdistani - Los Angeles CA, US
Michael Grunstein - Los Angeles, CA
David B. Seligson - Los Angeles CA, US
Michael Grunstein - Los Angeles, CA
David B. Seligson - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 39/395, G01N 33/574, A61P 43/00
US Classification:
4241381, 435 723
Abstract:
The present invention provides methods of diagnosing and providing a prognosis for a cancer by identifying cancers with altered global histone modification patterns using immunohistochemical techniques.
Therapeutic And Prognostic Factor Yy1 In Human Cancer
US Patent:
2008031, Dec 18, 2008
Filed:
Sep 9, 2005
Appl. No.:
11/662220
Inventors:
Benjamin Bonavida - Los Angeles CA, US
Lee Goodglick - Los Angeles CA, US
Hermes Gaban - Los Angeles CA, US
Stephan Horvath - Los Angeles CA, US
David Seligson - Los Angeles CA, US
Lee Goodglick - Los Angeles CA, US
Hermes Gaban - Los Angeles CA, US
Stephan Horvath - Los Angeles CA, US
David Seligson - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 49/00, C07H 21/04, A61P 35/00, A61K 33/00, A61K 31/7105, G01N 33/574, C12Q 1/68, C12Q 1/02
US Classification:
424 91, 536 2433, 424718, 514 44, 435 723, 435 6, 435 29
Abstract:
The present invention provides for the first time YY1, a transcription factor gene over-expressed and/or functionally overactive in human cancer. The present invention provides methods of diagnosing and providing a prognosis for cancer such as prostate cancer, as well as methods of drug discovery. YY1 is also a therapeutic target for treatment of cancer resistant to conventional and experimental cancer therapeutics. Inhibition of YY1 expression and/or activity sensitizes resistant tumor cells to cytotoxic treatments, including chemotherapy, radiation therapy, hormonal therapy, and immunotherapy.
Methods Of Renal Cell Carcinoma Prognosis And Treatment Selection With Carbonic Anhydrase Ix
US Patent:
2005015, Jul 21, 2005
Filed:
Apr 15, 2003
Appl. No.:
10/511465
Inventors:
Matthew Bui - Los Angeles CA, US
David Seligson - Los Angeles CA, US
Arie Belldegrun - Los Angeles CA, US
David Seligson - Los Angeles CA, US
Arie Belldegrun - Los Angeles CA, US
International Classification:
G01N033/574
US Classification:
435007230
Abstract:
The present invention provides methods of aiding in a renal cell carcinoma prognosis that include quantifying expressed carbonic anhydrase in samples derived from renal cell carcinoma patients. The methods also identify patients that are likely to respond positively to selected courses of treatment. The invention further provides related computer program products.